Dallah Healthcare Past Earnings Performance
Past criteria checks 5/6
Dallah Healthcare has been growing earnings at an average annual rate of 25.9%, while the Healthcare industry saw earnings growing at 20.3% annually. Revenues have been growing at an average rate of 21.2% per year. Dallah Healthcare's return on equity is 13.5%, and it has net margins of 14.7%.
Key information
25.9%
Earnings growth rate
23.2%
EPS growth rate
| Healthcare Industry Growth | 12.3% |
| Revenue growth rate | 21.2% |
| Return on equity | 13.5% |
| Net Margin | 14.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
With EPS Growth And More, Dallah Healthcare (TADAWUL:4004) Makes An Interesting Case
Dec 21
Some Shareholders Feeling Restless Over Dallah Healthcare Company's (TADAWUL:4004) P/E Ratio
Oct 31The Return Trends At Dallah Healthcare (TADAWUL:4004) Look Promising
Oct 07Do Dallah Healthcare's (TADAWUL:4004) Earnings Warrant Your Attention?
Sep 19Dallah Healthcare Company (TADAWUL:4004) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 14The Price Is Right For Dallah Healthcare Company (TADAWUL:4004)
Jul 18Investors Will Want Dallah Healthcare's (TADAWUL:4004) Growth In ROCE To Persist
May 30We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease
Apr 16What You Can Learn From Dallah Healthcare Company's (TADAWUL:4004) P/E
Mar 18Returns On Capital At Dallah Healthcare (TADAWUL:4004) Have Hit The Brakes
Feb 25Dallah Healthcare (TADAWUL:4004) Has More To Do To Multiply In Value Going Forward
Oct 30Dallah Healthcare (TADAWUL:4004) Is Reinvesting At Lower Rates Of Return
Jul 26Returns On Capital Signal Tricky Times Ahead For Dallah Healthcare (TADAWUL:4004)
Apr 17Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?
Feb 06Dallah Healthcare (TADAWUL:4004) Will Want To Turn Around Its Return Trends
Dec 05We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease
Nov 01Calculating The Intrinsic Value Of Dallah Healthcare Company (TADAWUL:4004)
Aug 28Dallah Healthcare (TADAWUL:4004) Has Some Way To Go To Become A Multi-Bagger
Aug 12Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching
Jul 28Industry Analysts Just Upgraded Their Dallah Healthcare Company (TADAWUL:4004) Revenue Forecasts By 10%
May 26Calculating The Fair Value Of Dallah Healthcare Company (TADAWUL:4004)
May 20Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching
Apr 16Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively
Feb 03Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?
Jan 10Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively
Oct 19Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively
Jul 09Forecast: Analysts Think Dallah Healthcare Company's (TADAWUL:4004) Business Prospects Have Improved Drastically
Jun 16Broker Revenue Forecasts For Dallah Healthcare Company (TADAWUL:4004) Are Surging Higher
May 02What Kind Of Shareholders Hold The Majority In Dallah Healthcare Company's (TADAWUL:4004) Shares?
Mar 17Has Dallah Healthcare (TADAWUL:4004) Got What It Takes To Become A Multi-Bagger?
Mar 02Dallah Healthcare (TADAWUL:4004) Shareholders Booked A 45% Gain In The Last Year
Feb 15Should You Buy Dallah Healthcare Company (TADAWUL:4004) For Its Dividend?
Feb 01Are Dallah Healthcare's (TADAWUL:4004) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 05
Dallah Healthcare Company's (TADAWUL:4004) Intrinsic Value Is Potentially 26% Below Its Share Price
Dec 22Will Dallah Healthcare (TADAWUL:4004) Multiply In Value Going Forward?
Nov 20Revenue & Expenses Breakdown
How Dallah Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,203 | 471 | 591 | 0 |
| 30 Jun 24 | 3,105 | 444 | 580 | 0 |
| 31 Mar 24 | 3,010 | 385 | 565 | 0 |
| 31 Dec 23 | 2,943 | 360 | 549 | 0 |
| 30 Sep 23 | 2,831 | 325 | 516 | 0 |
| 30 Jun 23 | 2,682 | 270 | 487 | 0 |
| 31 Mar 23 | 2,595 | 286 | 456 | 0 |
| 31 Dec 22 | 2,488 | 274 | 443 | 0 |
| 30 Sep 22 | 2,370 | 305 | 464 | 0 |
| 30 Jun 22 | 2,313 | 311 | 450 | 0 |
| 31 Mar 22 | 2,220 | 289 | 434 | 0 |
| 31 Dec 21 | 2,105 | 259 | 416 | 0 |
| 30 Sep 21 | 1,935 | 202 | 402 | 0 |
| 30 Jun 21 | 1,742 | 206 | 371 | 0 |
| 31 Mar 21 | 1,498 | 165 | 331 | 0 |
| 31 Dec 20 | 1,318 | 132 | 307 | 0 |
| 30 Sep 20 | 1,257 | 150 | 277 | 0 |
| 30 Jun 20 | 1,207 | 123 | 272 | 0 |
| 31 Mar 20 | 1,246 | 131 | 287 | 0 |
| 31 Dec 19 | 1,252 | 147 | 286 | 0 |
| 30 Sep 19 | 1,227 | 110 | 304 | 0 |
| 30 Jun 19 | 1,206 | 115 | 295 | 0 |
| 31 Mar 19 | 1,193 | 119 | 293 | 0 |
| 31 Dec 18 | 1,181 | 142 | 286 | 0 |
| 30 Sep 18 | 1,189 | 172 | 281 | 0 |
| 30 Jun 18 | 1,203 | 217 | 274 | 0 |
| 31 Mar 18 | 1,218 | 268 | 260 | 0 |
| 31 Dec 17 | 1,212 | 295 | 246 | 0 |
| 30 Sep 17 | 1,202 | 284 | 254 | 0 |
| 30 Jun 17 | 1,180 | 268 | 265 | 0 |
| 31 Mar 17 | 1,181 | 252 | 275 | 0 |
| 31 Dec 16 | 1,163 | 225 | 288 | 0 |
| 30 Sep 16 | 1,122 | 228 | 264 | 0 |
| 30 Jun 16 | 1,073 | 194 | 255 | 0 |
| 31 Mar 16 | 1,030 | 175 | 249 | 0 |
| 31 Dec 15 | 985 | 165 | 231 | 0 |
| 30 Sep 15 | 948 | 161 | 219 | 0 |
| 30 Jun 15 | 917 | 156 | 211 | 0 |
| 31 Mar 15 | 892 | 154 | 206 | 0 |
| 31 Dec 14 | 859 | 147 | 201 | 0 |
| 30 Sep 14 | 831 | 149 | 203 | 0 |
| 30 Jun 14 | 805 | 149 | 194 | 0 |
| 31 Mar 14 | 773 | 138 | 184 | 0 |
| 31 Dec 13 | 750 | 137 | 182 | 0 |
Quality Earnings: 4004 has high quality earnings.
Growing Profit Margin: 4004's current net profit margins (14.7%) are higher than last year (11.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4004's earnings have grown significantly by 25.9% per year over the past 5 years.
Accelerating Growth: 4004's earnings growth over the past year (44.9%) exceeds its 5-year average (25.9% per year).
Earnings vs Industry: 4004 earnings growth over the past year (44.9%) exceeded the Healthcare industry 13.5%.
Return on Equity
High ROE: 4004's Return on Equity (13.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 05:09 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dallah Healthcare Company is covered by 22 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ibrahim Elaiwat | Aljazira Capital Company |
| Jassim Al-Jubran | Aljazira Capital Company |
| Rim Ben Salah Gharbi | AlphaMena |